Safety
NSCLC, PDAC
NSCLC
The median duration of oleclumab exposure was 8.0 weeks in the monotherapy (range, 2.0–51.9) and combination therapy (range, 2.0–43.9) escalation cohorts and in the expansion cohorts combined (range, 2.0–188.1); 5 patients in the expansion cohorts (1 MSS-CRC, 1 PDAC, 3 NSCLC) received treatment for ≥ 64 weeks. Median (range) duration of exposure to durvalumab was the same as for oleclumab in the combination therapy escalation cohort and in the expansion cohorts.